data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
CytomX Therapeutics
(NASDAQ:CTMX)
1.90
0.03[1.60%]
At close: Jun 24
1.90
00
After Hours: 5:17PM EDT
Day High/Low1.85 - 2
52 Week High/Low1.51 - 7.53
Open / Close1.95 / 1.9
Float / Outstanding64.7M / 65.4M
Vol / Avg.10.4M / 1.1M
Mkt Cap124.3M
P/E-
50d Avg. Price1.78
Div / Yield-
Payout Ratio-
EPS-0.37
Total Float64.7M

CytomX Therapeutics (NASDAQ:CTMX), Quotes and News Summary

CytomX Therapeutics (NASDAQ: CTMX)

Day High/Low1.85 - 2
52 Week High/Low1.51 - 7.53
Open / Close1.95 / 1.9
Float / Outstanding64.7M / 65.4M
Vol / Avg.10.4M / 1.1M
Mkt Cap124.3M
P/E-
50d Avg. Price1.78
Div / Yield-
Payout Ratio-
EPS-0.37
Total Float64.7M
Benzinga - 1 day ago
Benzinga - 1 day ago
Benzinga - May 26, 2022, 10:18AM
Benzinga - May 26, 2022, 8:05AM
Benzinga - May 5, 2022, 5:52PM
Benzinga - Mar 17, 2022, 8:07AM
Benzinga - Mar 2, 2022, 10:25AM
Benzinga - Mar 1, 2022, 5:07PM
Benzinga - Feb 7, 2022, 9:17AM
Benzinga - Jan 19, 2022, 8:17AM
Benzinga - Jan 18, 2022, 7:21AM
load more
Sector: Health Care.Industry: Biotechnology
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.360-0.370 -0.0100
REV20.660M17.136M-3.524M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

CytomX Therapeutics Questions & Answers

Q
How do I buy CytomX Therapeutics (CTMX) stock?
A

You can purchase shares of CytomX Therapeutics (NASDAQ: CTMX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are CytomX Therapeutics's (CTMX) competitors?
Q
What is the target price for CytomX Therapeutics (CTMX) stock?
A

The latest price target for CytomX Therapeutics (NASDAQ: CTMX) was reported by BMO Capital on Friday, June 24, 2022. The analyst firm set a price target for 9.00 expecting CTMX to rise to within 12 months (a possible 373.68% upside). 5 analyst firms have reported ratings in the last year.

Q
Current Stock Price for CytomX Therapeutics (CTMX)?
A

The stock price for CytomX Therapeutics (NASDAQ: CTMX) is $1.9 last updated June 24, 2022, 8:00 PM UTC.

Q
Does CytomX Therapeutics (CTMX) pay a dividend?
A

There are no upcoming dividends for CytomX Therapeutics.

Q
When is CytomX Therapeutics (NASDAQ:CTMX) reporting earnings?
A

CytomX Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is CytomX Therapeutics (CTMX) going to split?
A

There is no upcoming split for CytomX Therapeutics.

Q
What sector and industry does CytomX Therapeutics (CTMX) operate in?
A

CytomX Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.